



# **New Frontiers: Manufacturing a Protein-Based Artificial Retina in Low-Earth Orbit**

Nicole L. Wagner, PhD, CEO  
March 29, 2023

# LAMBDAVISION OVERVIEW

## Company Overview

- **Founded:** Dr. Robert Birge, Distinguished Professor, UConn
- **Stage:** Preclinical
- **Funding:** >\$10M

## Market Opportunity


- **Product:** Bacteriorhodopsin-based artificial retina
- **Lead Indication:** Advanced retinitis pigmentosa
  - 100K US, 1.5M Worldwide (~1 in 4000)
- **Follow-on Indication:** Age-related macular degeneration
  - 10M US, ~50M Worldwide
- **Current Treatments:** No cure exists, and there is an unmet need to restore meaningful vision to those affected.



# CURRENT TREATMENTS FOR RETINITIS PIGMENTOSA




**Normal Vision**



**State of the Art**

## LAMBD AVISION'S SOLUTION



**PROTEIN-BASED ARTIFICIAL RETINA**







- High resolution
- Simpler surgery
- Small, flexible, and long-lasting implant
- Replaces function of rods and cones



# PROTEIN-BASED ARTIFICIAL RETINAS

The artificial retina is comprised of oriented layers of the light-activated proton pump, bacteriorhodopsin.




Birge, R.R. et al. J. Phys. Chem. B. 1999; 103: 10746-1076.

Essen, J.O. et al. Curr. Opin. Struct. Biol. 2002;12:516-522

Greco J.A, et al.. J. Neural Eng. 2021, 18, 066027

# PROTEIN-BASED ARTIFICIAL RETINAS


The artificial retina creates a unidirectional ion gradient that activates the remaining retinal cell network.



# WHY MICROGRAVITY?

## Multilayered Thin Films Generated by Layer-by-Layer Assembly

- Manufacturing process is subject to the effects of gravity.
- Sedimentation of solutions reduces implant homogeneity.
- Inefficient, irregular protein deposition impacts artificial retina performance.
- Reduction in usable area for preclinical experiments and clinical trials.







# WHY MICROGRAVITY?

## Multilayered Thin Films Generated by Layer-by-Layer Assembly


- Manufacturing process is subject to the effects of gravity.
- Sedimentation of solutions reduces implant homogeneity.
- Inefficient, irregular protein deposition impacts artificial retina performance.
- Reduction in usable area for preclinical experiments and clinical trials.




**EARTH**



**MICROGRAVITY**






**EARTH**



**MICROGRAVITY**



# ISS NATIONAL LAB MANUFACTURING



## MICROGRAVITY ENHANCES THE 3-DIMENSIONAL ASSEMBLY OF FILMS

- **Stable.** Improved homogeneity, stability, and performance.
- **Practical.** BR stability allows for manufacturing and storage in an ambient environment.
- **Efficient.** Automated process limits astronaut time and ISS resources.
- **Feasible.** Manageable production volumes required to supply clinical trials

# NASA SUPPORT ADVANCES ARTIFICIAL RETINA DEVELOPMENT

**LambdaVision**, along with Space Tango secured ~\$7M in contract funds to explore benefits of microgravity on production of the artificial retina.


- **LambdaVision** won CASIS/Boeing prize from MassChallenge in 2016.
- Pathfinder mission on SpaceX-16 in December 2018 demonstrated promising results.
- NASA Phase I/II SBIR and NRA awards supported 6 flights over 3 years to the International Space Station to evaluate and improve on-orbit processes for layer-by-layer deposition of proteins.
- Research and development supported by NASA/ISSNL is foundational and can support process improvements across a number of technology applications.
- NASA and ISSNL funding is critical in supporting chemistry manufacturing controls and assay development required for commercialization of the artificial retina and future technologies in LEO.






# ISS NATIONAL LAB MANUFACTURING


Seven missions on the ISS National Lab have been completed via NASA SBIR and NRA funding (SpaceX CRS-16, NG-14, NG-15, SpaceX CRS-24, Crew 4, Crew 5, and SpaceX CRS-24)




200 layer film (PAR04 – CH1)



50 layer film (PAR04 – CH2)







200 layer film (PAR05 – CH1)



200 layer film (PAR05 – CH2)





# PAR04 AND PAR05 DEINTEGRATION



## SUMMARY

- The fluidics, operational controls, and in-process quality measurements were validated through the assembly of multiple artificial retina thin films in microgravity.
- Multiple 200-layer thin films have been manufactured in microgravity and we have a proven tech stack of the CubeLab™ with good control and automation.
- Post-flight characterization on the flight solutions demonstrated no discernable change to protein and polymer quality.
- In vitro assay development is ongoing to further evaluate the functionality of post-flight samples.
- Additional flights planned to optimize manufacturing parameters, advance hardware, and evaluate opportunities for scale

# BROADER IMPACTS



## FUTURE OF LAYER-BY-LAYER MANUFACTURING IN MICROGRAVITY

### Bacteriorhodopsin-Based Applications

- Artificial Retina
- Optical Data Storage
- Associative Processing/Neural Networks
- Optical Pattern Recognition
- Chemical/Environmental Toxin Detection

### Additional Opportunities

- Biosensors
- Wound Healing
- Tissue Engineering
- Anti-Biofouling
- Products requiring good manufacturing practices



# LEO COMMERCIALIZATION

- Leverage ISS capabilities and current flight opportunities to explore commercial development in LEO
- Demonstrate feasibility of biomanufacturing in microgravity and in space production of advanced materials
- Inspire new research and commercial product development that can foster a thriving LEO economy
- Promote dialogue around transition of ISS to CLDs and the development of business models for LEO
- Establish a robust ecosystem that supports in space production of products that have the potential to improve life for people on Earth

[lambdavisio.com](http://lambdavisio.com)



Dr. Nicole L. Wagner, PhD, CEO  
[nicole.wagner@lambdavisio.com](mailto:nicole.wagner@lambdavisio.com)  
774-280-0525

